The Effectiveness of Cispresa Cream Compared to Tri-luma Formulation in the Treatment of Melasma

Evaluating the Effectiveness of Cispersa Cream Compared to Tri-luma Formulation in the Treatment of Melasma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220919055994N3

Enrollment

Registered

2025-11-04

Start date

2025-11-05

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention 1: Intervention group: Patients Receiving the Drug Cispresa Cream. Intervention 2: Intervention group: Patients Receiving Tri-Luma Formulation Cream.

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: People with Melasma Age 20 to 65 Years

Exclusion criteria

Exclusion criteria: Concomitant use of other topical Medications in the past four Weeks Koebner-Positive Diseases such as Vitiligo Autoimmune Diseases Hyperpigmentation Taking Immunosuppressive Medications Cancer Patients Patients Undergoing Chemotherapy Breastfeeding and Pregnancy

Design outcomes

Primary

Measure	Time frame
Melasma Treatment. Timepoint: Two Months. Method of measurement: Examination by Maxometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Rastaghi

Kerman University of Medical Sciences

fatemeh_rastaghi@yahoo.com+98 34 3132 8328

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026